Population pharmacokinetics of methylprednisolone in accident victims with spinal cord injury

International Journal of Clinical Pharmacology and Therapeutics

Volumn 42, Issue 9, 2004, Pages 504-511

  Barth, Juergen ^a,b   Winkler, J ^c   Schumann, R ^b   Nagaraja, N V ^c   Madabushi, R ^c   Balbach, S ^c   Derendorf, H ^c   Mollmann H ^b   Mollenhoff G ^b  

^a BG KLINIKEN BERGMANNSTROST   (Germany)

^b RUHR UNIVERSITY BOCHUM   (Germany)

^c UNIVERSITY OF FLORIDA   (United States)

Author keywords

Acute spinal cord injury; CSF; Methylprednisolone; Methylprednisolone hemisuccinate; NONMEM; Population pharmacokinetics; Saliva

Indexed keywords

METHYLPREDNISOLONE; METHYLPREDNISOLONE SODIUM SUCCINATE; PRODRUG;

ACUTE DISEASE; ADOLESCENT; ADULT; AGED; BOLUS INJECTION; CLINICAL ARTICLE; COMPARTMENT MODEL; COMPUTER PROGRAM; DRUG BLOOD LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG DOSE REGIMEN; DRUG MEGADOSE; DRUG METABOLISM; DRUG MONITORING; DRUG SALIVA LEVEL; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; REVIEW; SPINAL CORD INJURY; STEADY STATE; TRAFFIC ACCIDENT;

EID: 4544314035     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CPP42504     Document Type: Review

References (31)

1. Bracken MB, Shepard MJ, Collins WF, Holford TR, Young W, Baskin DS, Eisenberg HM, Flamm E, Leo-Summers L, Maroon J et al 1990 A randomized, controlled trial of methylprednisolone or naloxone in the treatment of acute spinal-cord injury. Results of the Second National Acute Spinal Cord Injury Study (see comments). N Engl J Med 322: 1405-1411
2. Bracken MB 1993 Pharmacological treatment of acute spinal cord injury: current status and future projects. J Emerg Med 11: 43-48
3. Bracken MB, Shepard MJ, Holford TR, Leo-Summers L, Aldrich EF, Fazl M, Fehlings M, Herr DL, Hitchon PW, Marshall LF, Nockels RP, Pascale V, Perot PL Jr, Piepmeier J, Sonntag VK, Wagner F, Wilberger JE, Winn HR, Young W 1997 Administration of methylprednisolone for 24 or 48 hours or tirilazad mesylate for 48 hours in the treatment of acute spinal cord injury. Results of the Third National Acute Spinal Cord Injury Randomized Controlled Trial. National Acute Spinal Cord Injury Study. JAMA 277: 1597-1604
4. Braughler JM, Hall ED 1982 Pharmacokinetics of methylprednisolone in cat plasma and spinal cord following a single intravenous dose of the sodium succinate ester. Drug Metab Dispos 10: 551-552
5. Defer GL, Barre J, Ledudal P, Tillement JP, Degos JD 1995 Methylprednisolone infusion during acute exacerbation of MS: plasma and CSF concentrations. Eur Neurol 35: 143-148
6. Derendorf H, Mollmann H, Rohdewald P, Rehder J, Schmidt EW 1985 Kinetics of methylprednisolone and its hemisuccinate ester. Clin Pharmacol Ther 37: 502-507
7. Derendorf H, Mollmann H, Krieg M, Tunn S, Mollmann C, Barth J, Rothig HJ 1991 Pharmacodynamics of methylprednisolone phosphate after single intravenous administration to healthy volunteers. Pharm Res 8: 263-268
8. Ducker TB, Zeidman SM 1994 Spinal cord injury. Role of steroid therapy. Spine 19: 2281-2287
9. Faure C, Andre J, Pelatan C, Munck A, Giraud M, Cezard JP, Jacqz-Aigrain E 1998 Pharmacokinetics of intravenous methylprednisolone and oral prednisone in paediatric patients with inflammatory bowel disease during the acute phase and in remission. Eur J Clin Pharmacol 54: 555-560
10. Ferry JJ, Della-Coletta AA, Weber DJ, VanderLugt JT 1994 Pilot study of the pharmacokinetics of methylprednisolone after single and multiple intravenous doses of methylprednisolone sodium succinate and methylprednisolone suleptanate to healthy volunteers. J Clin Pharmacol 34: 1109-1115
11. Hall ED, Braughler JM 1982 Glucocorticoid mechanisms in acute spinal cord injury: a review and therapeutic rationale. Surg Neurol 18: 320-327
12. Hattori K, Kamio M, Nakajima E, Oshima T, Satoh T, Kitagawa H 1981 Characterization of steroid hormone ester hydrolyzing enzymes in liver microsomes. Biochem Pharmacol 30: 2051-2056
13. Hayball PJ, Cosh DG, Ahern MJ, Schultz DW, Roberts-Thomson PJ 1992 High dose oral methylprednisolone in patients with rheumatoid arthritis: pharmacokinetics and clinical response. Eur J Clin Pharmacol 42: 85-88
14. Hilton G, Frei J 1991 High-dose methylprednisolone in the treatment of spinal cord injuries. Heart Lung 20: 675-680
15. Janssen L, Hansebout RR 1989 Pathogenesis of spinal cord injury and newer treatments. A review. Spine 14: 23-32
16. Kong AN, Jungbluth GL, Pasko MT, Beam TR, Jusko WJ 1990 Pharmacokinetics of methylprednisolone sodium succinate and methylprednisolone in patients undergoing cardiopulmonary bypass. Pharmacotherapy 10: 29-34
17. Koszdin KL, Shen DD, Bernards CM 2000 Spinal cord bioavailability of methylprednisolone after intravenous and intrathecal administration: the role of P-glycoprotein. Anesthesiology 92: 156-163
18. Langley LL 1971 Physiology of man. Van Nostrand Company, New York, p 409
19. Ludwig EA, Kong AN, Camara DS, Jusko WJ 1993 Pharmacokinetics of methylprednisolone hemisuccinate and methylprednisolone in chronic liver disease. J Clin Pharmacol 33: 805-810
20. Mollmann H, Rohdewald P, Barth J, Mollmann C, Verho M, Derendorf H 1988 Comparative pharmacokinetics of methylprednisolone phosphate and hemisuccinate in high doses. Pharm Res 5: 509-513
21. Mollmann H, Rohdewald P, Barth J, Verho M, Derendorf H 1989 Pharmacokinetics and dose linearity testing of methylprednisolone phosphate. Biopharm Drug Dispos 10: 453-464
22. Mollmann H, Hochhaus G, Rohatagi S, Barth J, Derendorf H 1995 Pharmacokinetic/pharmacodynamic evaluation of deflazacort in comparison to methylprednisolone and prednisolone. Pharm Res 12: 1096-1100
23. Parker TJ, Daley-Yates PT, Wood SA 1997 A comparative population pharmacokinetic analysis for methylprednisolone following multiple dosing of two prodrugs in patients with acute asthma. Br J Clin Pharmacol 43: 589-592
24. Parnes LS, Sun AH, Freeman DJ 1999 Corticosteroid pharmacokinetics in the inner ear fluids: an animal study followed by clinical application. Laryngoscope 109: 1-17
25. Rohdewald P, Rehder J, Drehsen G, Hochhaus G, Derendorf H, Mollmann H 1985 Simultaneous determination of glucocorticoid alcohols, their succinates and hydrocortisone in plasma. J Pharm Biomed Anal 3: 565-573
26. Saitoh H, Hatakeyama M, Eguchi O, Oda M, Takada M 1998 Involvement of intestinal P-glycoprotein in the restricted absorption of methylprednisolone from rat small intestine. J Pharm Sci 87: 73-75
27. Segal JL, Maltby BF, Langdorf MI, Jacobson R, Brunnemann SR, Jusko WJ 1998 Methylprednisolone disposition kinetics in patients with acute spinal cord injury. Pharmacotherapy 18: 16-22
28. Ueda K, Okamura N, Hirai M, Tanigawara Y, Saeki T, Kioka N, Komano T, Hori R 1992 Human P-glycoprotein transports cortisol, aldosterone, and dexamethasone, but not progesterone. J Biol Chem 267: 24248-24252
29. van Asperen J, Mayer U, van Tellingen O, Beijnen JH 1997 The functional role of P-glycoprotein in the blood-brain barrier. J Pharm Sci 86: 881-884
30. van Kalken CK, Broxterman HJ, Pinedo HM, Feller N, Dekker H, Lankelma J, Giaccone G 1993 Cortisol is transported by the multidrug resistance gene product P-glycoprotein. Br J Cancer 67: 284-289
31. Young W, Kume-Kick J, Constantini S 1994 Glucocorticoid therapy of spinal cord injury. Ann N Y Acad Sci 743: 241-265